The SOLO-3 late-stage trial, which evaluated the efficacy and safety of Lynparza, featured 266 patients whose ovarian cancer relapsed following two or more lines of treatment. Patients were
The post AstraZeneca’s Lynparza succeeds in SOLO-3 ovarian cancer trial appeared first on Pharmaceutical Business review.
Original Article: AstraZeneca’s Lynparza succeeds in SOLO-3 ovarian cancer trial